Oncocyte launches VitaGraft Kidney test for transplant monitoring

Insight Molecular Diagnostics Inc.

VitaGraft Kidney, a blood-based dd-cfDNA test for kidney transplant rejection, is now broadly available upon request.
Previously limited to Oncocyte's Early Access Program; official launch announced via LinkedIn on Jan 22, 2024.
Test measures donor-derived cell-free DNA concentrations post-transplantation as indicator for organ damage or rejection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.